DRREDDY

Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY

1,342.00 INR−10.00 −0.74%

Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY) last traded at 1,342.00 INR, down 0.74% on the day. Over the past year the stock is up 11.60%. Its 52-week range is 1,101.00 to 1,414.90. It is in the Health Technology sector (Pharmaceuticals: Major).

Key statistics

Open1,352.00

Day range1,336.70 – 1,364.90

52-week range1,101.00 – 1,414.90

Volume1.97 M

Average volume (10 days)2.73 M

Market cap (USD)11.86 B

P/E39.99

EPS (TTM) (USD)0.3496

Dividend yield0.59%

Beta (1 year)0.2084

Revenue (TTM) (USD)3.44 B

Employees27.53 K

Performance

+6.51%1 week

+8.84%1 month

+14.31%3 months

+4.68%6 months

+5.67%Year to date

+11.60%1 year

Technical rating

Buy

Daily summary of 11 oscillators and 15 moving averages. See every indicator

Analysts’ target

1,361.65 INR

The average 1-year price target, +1.46% from the last price. See the forecast

Latest headlines

Weekly Recap: Q2 beat and U.S. intravenous abatacept Dec 2026TradingView · 02 Nov 2026
Dr. Reddy's Laboratories Ltd Stock 12‑Month Price Target Raised to $14.25, Implies 1% UpsideTradingView · 30 Oct 2026
Buzzing stocks: TVS Motor, Fortis Healthcare, Dr Reddy’s, Bajaj Electricals, Titagarh, Zaggle, Awfis, HD Fire, KIMS, ShalbyBusiness Line · 29 Oct 2026
NPPA revises MRP of 543 anti-cancer medicine brands; new prices effective from November 9Asian News International · 28 Oct 2026
Dr Reddy's Says USFDA Classifies Inspection Outcome As Vai And Inspection Officially ClosedReuters · 28 Oct 2026
Dr Reddy's stock could rise 10-15% if a major biosimilar gets approved in December: SystematixCNBC TV18 · 27 Oct 2026
Dr. Reddy's Laboratories Ltd Stock 12‑Month Price Target Raised to $14.01, Implies 6% UpsideTradingView · 26 Oct 2026
Dr Reddy's Q2 profit falls 36%, plans semaglutide relaunch in NovemberMint · 26 Oct 2026

Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.